AstraZeneca, Daiichi Sankyo continue earlier-line breast cancer push with Phase III Enhertu win
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu significantly improved progression-free survival in metastatic breast patients with low and ultralow HER2 expression levels who had received at least one line of systemic treatment.